A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
-
Published:2023-10
Issue:5
Volume:8
Page:101623
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Al-Batran S.-E.,
Mueller D.W.,
Rafiyan M.-R.,
Kiselicki D.,
Atmaca A.,
Habibzada T.,
Mueller C.,
Brignone C.,
Triebel F.,
Loose M.ORCID,
Schaaf M.,
Sookthai D.,
Eickhoff R.,
Jaeger E.,
Goetze T.O.
Subject
Cancer Research,Oncology